Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Bought by Millennium Management LLC

Millennium Management LLC grew its stake in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 69.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,192,158 shares of the biopharmaceutical company's stock after acquiring an additional 900,743 shares during the period. Millennium Management LLC owned about 3.35% of Regulus Therapeutics worth $3,464,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its holdings in Regulus Therapeutics by 141.2% during the 4th quarter. JPMorgan Chase & Co. now owns 190,457 shares of the biopharmaceutical company's stock worth $301,000 after acquiring an additional 111,485 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Regulus Therapeutics by 20.5% in the 4th quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock worth $185,000 after buying an additional 19,900 shares during the last quarter. Barclays PLC lifted its position in shares of Regulus Therapeutics by 13.9% in the 4th quarter. Barclays PLC now owns 96,247 shares of the biopharmaceutical company's stock worth $152,000 after buying an additional 11,770 shares during the last quarter. Finally, PEAK6 LLC bought a new position in shares of Regulus Therapeutics in the 4th quarter worth about $95,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on RGLS shares. Wall Street Zen started coverage on shares of Regulus Therapeutics in a research report on Sunday, May 18th. They issued a "sell" rating on the stock. Leerink Partnrs downgraded shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Leerink Partners restated a "market perform" rating and issued a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research report on Friday, March 14th. Finally, Jones Trading reiterated a "hold" rating and issued a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Regulus Therapeutics presently has an average rating of "Hold" and an average price target of $8.50.

Regulus Therapeutics Stock Up 0.4%

Regulus Therapeutics stock traded up $0.03 during trading hours on Tuesday, hitting $7.97. 425,212 shares of the company traded hands, compared to its average volume of 907,191. The firm has a market cap of $551.79 million, a P/E ratio of -7.45 and a beta of 0.49. The firm's 50-day simple moving average is $4.85 and its two-hundred day simple moving average is $2.60. Regulus Therapeutics Inc. has a 1-year low of $0.83 and a 1-year high of $8.20.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.14. On average, equities research analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.